Imatinib Completed Phase 2 Trials for Chronic Myeloid Leukemia (CML) / Minimal Residual Disease Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00858806Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy
NCT00514969Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase
NCT00219752Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
NCT00852566Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia
NCT00267085Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
NCT00219726Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation